Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986482 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A | EXPERIMENTAL | - |
| Part 1B1 | EXPERIMENTAL | - |
| Part 1B2 | EXPERIMENTAL | - |
| Part 1B3 | EXPERIMENTAL | - |
| Part 1C | EXPERIMENTAL | - |
| Part 2A | EXPERIMENTAL | - |
| Part 2B1 | EXPERIMENTAL | - |
| Part 2B2 | EXPERIMENTAL | - |
| Part 2B3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986482 | DRUG | Specified dose on specified days |
| Nivolumab and rHuPH20 | DRUG | Specified dose on specified days |
| Nivolumab/relatlimab/rHuPH20 | DRUG | Specified dose on specified days |
| Bevacizumab | DRUG | Specified dose on specified days |
Inclusion Criteria: * All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986482 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied alone or in combination with other therapies in patients with advanced solid tumors.
BMS-986482 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with advanced solid tumors.
BMS-986482 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory authority. The ongoing Phase 1 trial is currently recruiting participants with advanced solid tumors.
BMS-986482 is being studied in a Phase 1 clinical trial with the identifier NCT06697197. The trial is titled 'A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors' and is currently recruiting. The study is enrolling approximately 413 participants across multiple countries.
BMS-986482 is the primary name for this investigational drug. No alternative names have been identified for this compound. It is being developed by Bristol-Myers Squibb and is currently in Phase 1 clinical trials for advanced solid tumors.